<DOC>
	<DOCNO>NCT00627380</DOCNO>
	<brief_summary>We test safety efficacy 16-wk yoga lifestyle intervention oral glucose tolerance , fast lipid/lipoprotein level , body composition , cardiovascular function , quality life , CD4+ T-cell count viral load HIV-infected men woman component The Metabolic Syndrome . We hypothesize yoga lifestyle intervention improve metabolic , anthropometric , cardiovascular disease parameter , quality life domain without adversely affect immune virologic status people live HIV .</brief_summary>
	<brief_title>Yoga Management HIV-Metabolic Syndromes</brief_title>
	<detailed_description>Very safe , effective , novel treatment metabolic syndrome develop HIV-infected people exist . These metabolic syndrome may increase cardiovascular disease risk HIV-infected people may reduce quantity quality life . Practicing yoga lifestyle intervention may provide safe , effective novel therapy HIV metabolic syndrome , alternative form therapy test HIV-infected people metabolic syndrome . In men woman HIV-related metabolic syndrome , determine : 1 . The safety practice yoga lifestyle HIV-infected people treat HAART experience metabolic anthropometric syndrome . 2 . To quantify effect practice yoga lifestyle metabolic anthropomorphic syndrome HIV-infected people treat HAART experience syndrome . 3 . To quantify effect practice yoga lifestyle cardiovascular disease ( CVD ) risk HIV-infected people treated HAART increase CVD risk exist metabolic anthropomorphic syndrome .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Lipodystrophy</mesh_term>
	<criteria>HIVinfected volunteer must dyslipidemia ( fast serum LDLcholesterol &gt; 100mg/dL , triglyceride &gt; 200mg/dL , HDLcholesterol &lt; 40mg/dL ( men ) &lt; 50mg/dL ( woman ) , impair glucose tolerance ( fast blood glucose 100140mg/dL fast insulin 1345µU/mL 2hr glucose oGTT 140200mg/dL ) , central adiposity ( waist circumference &gt; 102 cm ( 40inches men ) &gt; 88cm ( 35inches woman ) The purpose identify enroll participant clear proatherogenic lipid profile increase CVD risk abdominal adiposity , fast glucose intolerance insulin resistance type 2 diabetic normalized blood sugar use glucoselowering agent . If type 2 diabetic us glucoselowering medication , still insulin resistant/glucose intolerant ( criterion ) , eligible participate , test add benefit yoga therapy define dysmetabolic syndrome participant stable standardofcare metabolic syndrome , include glucose lipidlowering agent These criterion must meet , even volunteer receive glucose lipidlowering agent , enroll participant develop metabolic syndrome normalized traditional pharmacologic approach Volunteers receive glucose lipidlowering agent normalized lipid , glucose insulin level define limit , eligible enroll . Additional Inclusion Criteria . 1870 year old . Plasma HIV RNA &lt; 15,000 copies/ml previous 3months . CD4 count &gt; 200 c/µL previous 3 month . Stable HIV RNA level stable CD4 count least past 3 month . Some HIVinfected people accomplish receive HAART ( eg . long term nonprogressors ) include . But , participant HAART regimen include either 2 NRTIs + NNRTI , 2NRTIs + PI , NRTI+NNRTI+PI `` Normal '' blood chemistry least 1 month prior enrollment : platelet count &gt; 30,000/mm3 absolute neutrophil count &gt; 750/mm3 transaminase &lt; 5x upper limit normal creatinine &lt; 3x upper limit normal albumin &gt; 30g/L Chronic hepatitis B infection ( HB surface antigen positive ) . Active hepatitis C infection ( detectable Hep C RNA ) . Those cleared hepatitis B C infection eligible . Diabetes [ fast glucose &gt; 140 mg/dL , fast insulin &gt; 45 µU/mL , 2hr glucose &gt; 200mg/dL ] . History diabetes mellitus predate HIVinfection . Medications agent regulate glucose lipid metabolism ( e.g. , insulinsensitizers , insulinsecretagogues , HMGCoA reductase inhibitor ( 'statins ' ) , fibrates , niacin ) permit . A large percentage ACTU subject ID Clinic patient receive RTVboosted regimen also receive lipidlowering agent . Excluding might significantly reduce pool potential enrollee . The glucose lipidlowering agent dose must stable least 3 month prior screen . Additionally , volunteer take glucoseor lipidlowering agent must still dyslipidemia impaired glucose tolerance criterion ( ) . If take agent 'normalized ' lipids/lipoproteins hyperinsulinemia , eligible Gestational diabetes , pregnancy , nurse mother . Menstruating woman must negative urine pregnancy test within 14 day prior DEXA test ( minor radiation exposure DEXA ) . To control potential metabolic effect alteration female hormone menstrual cycle , menstruate woman test follicular phase . Hypogonadism [ total testosterone &lt; 200ng/dL ( men ) &lt; 15ng/dL ( woman ) ] ; thyroid disorder [ TSH &lt; 0.2 &gt; 12µIU/mL ] ; hypercortisolemia [ morning cortisol &gt; 22µg/dL ] . Replacement testosterone thyroid hormone human growth hormone normalize abnormal level acceptable , long treatment stable , blood testosterone , TSH IGF1 level within normal range . Unwilling unable attend supervise yoga session 3days/wk provide Brentwood Center Health Connectcare Clinic . Any condition might contraindicate yoga therapy ( disable neuromuscular musculoskeletal injury/disorder ) History serious cardiovascular disease ; MI , unstable angina , heart failure , congenital heart disease , coronary artery disease , rest STsegment depression &gt; 1mm , coronary artery bypass graft , stroke , sinus tachycardia , arrhythmia , premature atrial ventricular contraction , claudication . Bundle branch block exclusionary limit interpretability resting/exercise ECG . Cardiovascular contraindication maximal exercise testing Anticipated change antiHIV medication medication affect metabolism , within next 4months Welltrained athlete ( define &gt; 3 exercise training exposures/week ; &gt; 30min regimented exercise/exposure maintain least prior 4 week ) Active substance abuse ( eg , alcoholism , cocaine , heroin , crack , methamphetamine , phencyclidine ) Active secondary infection significant change chronic suppressive therapy opportunistic infection 1 month prior enrollment New serious systemic infection 3 week prior enrollment Recent episode hyperlactatemia lactic acidosis , esp . rapid weight loss Chronic renal insufficiency/failure comorbid condition ( eg . cancer , COPD ) alter metabolism Pancreatitis , celiac disease , cirrhosis Inadequate macronutrient energy intake , malabsorptive disorder determine research dietician Dementia condition would prevent voluntary informed consent compliance Other compound blind investigational new drug might affect metabolism confound data interpretation ( eg . RU486 , interleukin therapy , cytokinereceptor antagonist ) Oral glucocorticoid corticosteroid use within previous 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>diabetes</keyword>
	<keyword>dyslipidemia</keyword>
	<keyword>visceral adiposity</keyword>
	<keyword>subcutaneous adipose waste</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>hypertension</keyword>
	<keyword>endothelial function</keyword>
	<keyword>quality life</keyword>
	<keyword>Complementary Therapies</keyword>
</DOC>